314 related articles for article (PubMed ID: 9053471)
1. Tumor necrosis factor ligand-receptor system can predict treatment outcome in lymphoma patients.
Warzocha K; Salles G; Bienvenu J; Bastion Y; Dumontet C; Renard N; Neidhardt-Berard EM; Coiffier B
J Clin Oncol; 1997 Feb; 15(2):499-508. PubMed ID: 9053471
[TBL] [Abstract][Full Text] [Related]
2. Plasma levels of tumour necrosis factor and its soluble receptors correlate with clinical features and outcome of Hodgkin's disease patients.
Warzocha K; Bienvenu J; Ribeiro P; Moullet I; Dumontet C; Neidhardt-Berard EM; Coiffier B; Salles G
Br J Cancer; 1998 Jun; 77(12):2357-62. PubMed ID: 9649158
[TBL] [Abstract][Full Text] [Related]
3. Prognostic significance of TNF alpha and its p55 soluble receptor in malignant lymphomas.
Warzocha K; Salles G; Bienvenu J; Barbier Y; Bastion Y; Doche C; Rieux C; Coiffier B
Leukemia; 1997 Apr; 11 Suppl 3():441-3. PubMed ID: 9209418
[TBL] [Abstract][Full Text] [Related]
4. Elevated circulating levels of TNFalpha and its p55 soluble receptor are associated with an adverse prognosis in lymphoma patients.
Salles G; Bienvenu J; Bastion Y; Barbier Y; Doche C; Warzocha K; Gutowski MC; Rieux C; Coiffier B
Br J Haematol; 1996 May; 93(2):352-9. PubMed ID: 8639428
[TBL] [Abstract][Full Text] [Related]
5. The tumour necrosis factor family of receptors/ligands in the serum of patients with rheumatoid arthritis.
Robak T; Gladalska A; Stepień H
Eur Cytokine Netw; 1998 Jun; 9(2):145-54. PubMed ID: 9681390
[TBL] [Abstract][Full Text] [Related]
6. Serum-soluble tumor necrosis factor receptor 2 (sTNF-R2) level determines clinical outcome in patients with aggressive non-Hodgkin's lymphoma.
Goto N; Tsurumi H; Takemura M; Hara T; Sawada M; Kasahara S; Kanemura N; Yamada T; Shimizu M; Takahashi T; Tomita E; Seishima M; Takami T; Moriwaki H
Eur J Haematol; 2006 Sep; 77(3):217-25. PubMed ID: 16856931
[TBL] [Abstract][Full Text] [Related]
7. [Measurement of the serum concentrations of tumor necrosis factor alpha and its soluble receptors in normal and pre-eclamptic pregnant patients].
Núñez-González JR; Sanabria-Vera CJ; Romero-Adrián T
Invest Clin; 2001 Sep; 42(3):171-81. PubMed ID: 11552506
[TBL] [Abstract][Full Text] [Related]
8. Serum levels of p55 and p75 soluble TNF receptors in adult acute leukaemia at diagnosis: correlation with clinical and biological features and outcome.
Vinante F; Rigo A; Tecchio C; Morosato L; Nadali G; Ricetti MM; Krampera M; Zanolin E; Locatelli F; Gallati H; Chilosi M; Pizzolo G
Br J Haematol; 1998 Sep; 102(4):1025-34. PubMed ID: 9734654
[TBL] [Abstract][Full Text] [Related]
9. Serum IL-6, TNFalpha, p55 srTNFalpha, p75srTNFalpha, srIL-2alpha levels and disease activity in systemic lupus erythematosus.
Davas EM; Tsirogianni A; Kappou I; Karamitsos D; Economidou I; Dantis PC
Clin Rheumatol; 1999; 18(1):17-22. PubMed ID: 10088943
[TBL] [Abstract][Full Text] [Related]
10. Value of the determination of TNF-alpha in the plasma of patients with non-Hodgkins lymphoma.
Macia J; Gomez X; Esquerda A; Perez B; Callao V; Marzo C
Leuk Lymphoma; 1996 Feb; 20(5-6):481-6. PubMed ID: 8833407
[TBL] [Abstract][Full Text] [Related]
11. Serum interleukin 6 levels are elevated in lymphoma patients and correlate with survival in advanced Hodgkin's disease and with B symptoms.
Kurzrock R; Redman J; Cabanillas F; Jones D; Rothberg J; Talpaz M
Cancer Res; 1993 May; 53(9):2118-22. PubMed ID: 8481913
[TBL] [Abstract][Full Text] [Related]
12. [Serum tumor necrosis factor-alpha levels in non-Hodgkin's lymphoma patients and its relationship to prognosis].
Li D; Li G; Wang B
Zhonghua Zhong Liu Za Zhi; 1997 Jul; 19(4):293-6. PubMed ID: 11038763
[TBL] [Abstract][Full Text] [Related]
13. [The role of HLA DRB1 genetic polymorphisms in non-Hodgkin's lymphomas].
Kalinka E; Juszczyński P; Woszczek G; Borowiec M; Robak T; Kowalski ML; Biliński P; Coiffier B; Salles G; Warzocha K
Przegl Lek; 2005; 62(12):1422-6. PubMed ID: 16786764
[TBL] [Abstract][Full Text] [Related]
14. Serum values of tumour necrosis factor-alpha and of soluble tumour necrosis factor-R55 in melanoma patients.
Ocvirk J; Stabuc B; Rudolf Z; Galvani V; Curin-Serbec V
Melanoma Res; 2000 Jun; 10(3):253-8. PubMed ID: 10890379
[TBL] [Abstract][Full Text] [Related]
15. Non-Hodgkin's lymphomas: immunologic prognostic studies.
Hadzi-Pecova L; Petrusevska G; Stojanovic A
Prilozi; 2007 Jul; 28(1):39-55. PubMed ID: 17921917
[TBL] [Abstract][Full Text] [Related]
16. Serum levels of soluble receptors for tumor necrosis factor (p55 and p75 sTNFr) in endometrial cancer.
Gadducci A; Ferdeghini M; Fanucchi A; Annicchiarico C; Prato B; Prontera C; Facchini V; Genazzani AR
Anticancer Res; 1996; 16(5B):3125-8. PubMed ID: 8920779
[TBL] [Abstract][Full Text] [Related]
17. [The role of genetic polymorphisms within tumor necrosis factor promoter gene in non-Hodgkin's lymphomas].
Juszczyński P; Kalinka E; Woszczek G; Borowiec M; Robak T; Kowalski ML; Biliński P; Coiffiers B; Salles G; Warzocha K
Przegl Lek; 2005; 62(12):1417-21. PubMed ID: 16786763
[TBL] [Abstract][Full Text] [Related]
18. Factors that predict chemotherapy-induced myelosuppression in lymphoma patients: role of the tumor necrosis factor ligand-receptor system.
Voog E; Bienvenu J; Warzocha K; Moullet I; Dumontet C; Thieblemont C; Monneret G; Gutowski MC; Coiffier B; Salles G
J Clin Oncol; 2000 Jan; 18(2):325-31. PubMed ID: 10637246
[TBL] [Abstract][Full Text] [Related]
19. Circulating levels of TNF alpha and TNF receptor superfamily members in lymphoid neoplasia.
Metkar SS; Naresh KN; Manna PP; Srinivas V; Advani SH; Nadkarni JJ
Am J Hematol; 2000 Oct; 65(2):105-10. PubMed ID: 10996826
[TBL] [Abstract][Full Text] [Related]
20. Clinical relevance of soluble HLA-I and beta2-microglobulin levels in non-Hodgkin's lymphoma and Hodgkin's disease.
Albitar M; Vose JM; Johnson MM; Do KA; Day A; Jilani I; Kantarjian H; Keating M; O'Brien SM; Verstovsek S; Armitage JO; Giles FJ
Leuk Res; 2007 Feb; 31(2):139-45. PubMed ID: 16545870
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
